23,047 Shares in MaxCyte, Inc. (NASDAQ:MXCT) Bought by Graham Capital Management L.P.

Graham Capital Management L.P. acquired a new position in shares of MaxCyte, Inc. (NASDAQ:MXCT) in the fourth quarter, HoldingsChannel reports. The fund acquired 23,047 shares of the company’s stock, valued at approximately $96,000.

A number of other institutional investors have also made changes to their positions in MXCT. Tower Research Capital LLC TRC grew its stake in shares of MaxCyte by 123.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,564 shares of the company’s stock worth $31,000 after purchasing an additional 4,173 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of MaxCyte during the fourth quarter worth $56,000. Prudential Financial Inc. acquired a new stake in shares of MaxCyte during the fourth quarter worth $65,000. Catalyst Funds Management Pty Ltd acquired a new stake in shares of MaxCyte during the fourth quarter worth $74,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of MaxCyte by 10.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,366 shares of the company’s stock worth $93,000 after purchasing an additional 2,154 shares during the period. 68.81% of the stock is owned by institutional investors and hedge funds.

MaxCyte Trading Down 0.9%

MXCT stock opened at $2.28 on Tuesday. The business’s 50-day moving average price is $2.69 and its two-hundred day moving average price is $3.56. The firm has a market cap of $242.41 million, a PE ratio of -6.71 and a beta of 1.38. MaxCyte, Inc. has a 1-year low of $2.10 and a 1-year high of $5.26.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.10) earnings per share for the quarter, hitting the consensus estimate of ($0.10). The company had revenue of $10.39 million during the quarter, compared to analysts’ expectations of $9.05 million. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. On average, analysts forecast that MaxCyte, Inc. will post -0.42 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on MXCT shares. BTIG Research set a $6.00 target price on MaxCyte and gave the stock a “buy” rating in a report on Wednesday, March 12th. Stifel Nicolaus reduced their target price on MaxCyte from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, March 12th.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.